CD274 and neoplasm: This multimodal strategy aims to sequentially: 1) prime the TME through radiation-induced antigen release, 2) enhance systemic immunity via probiotic-mediated gut-immune axis modulation, 3) sustain tumor control with low-dose chemotherapy’s immunogenic effects, and 4) amplify immune recognition through PD-1/PD-L1 blockade.